Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Secular trends in hip fractures worldwide: opposing trends East versus West.

Ballane G, Cauley JA, Luckey MM, Fuleihan Gel-H.

J Bone Miner Res. 2014 Aug;29(8):1745-55. doi: 10.1002/jbmr.2218.

2.

Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M; FRAX(®) Position Conference Members..

J Clin Densitom. 2011 Jul-Sep;14(3):240-62. doi: 10.1016/j.jocd.2011.05.015.

PMID:
21810532
3.

FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Cauley JA, El-Hajj Fuleihan G, Luckey MM; FRAX(®) Position Development Conference Members..

J Clin Densitom. 2011 Jul-Sep;14(3):237-9. doi: 10.1016/j.jocd.2011.05.016.

PMID:
21810531
4.

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.

Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R; FRAX(®) Position Development Conference Members..

J Clin Densitom. 2011 Jul-Sep;14(3):171-80. doi: 10.1016/j.jocd.2011.05.007.

PMID:
21810521
5.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM; AACE Osteoporosis Task Force..

Endocr Pract. 2010 Nov-Dec;16 Suppl 3:1-37. No abstract available.

6.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM.

Endocr Pract. 2010 Nov-Dec;16(6):1016-9. No abstract available.

7.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators..

J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5.

8.

Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007.

Lewiecki EM, Bilezikian JP, Cooper C, Hochberg MC, Luckey MM, Maricic M, Miller PD.

J Clin Densitom. 2008 Apr-Jun;11(2):313-24. doi: 10.1016/j.jocd.2007.12.017. Epub 2008 Feb 14.

PMID:
18280193
9.

Bisphosphonates and osteonecrosis of the jaw.

Watts NB, Harris ST, McClung MR, Bilezikian JP, Greenspan SL, Luckey MM.

Ann Intern Med. 2006 Nov 21;145(10):791-2; author reply 792. No abstract available.

PMID:
17116933
10.

Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry.

Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC.

J Clin Densitom. 2005 Winter;8(4):371-8. Review.

PMID:
16311420
11.

Daily and cyclic parathyroid hormone in women receiving alendronate.

Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R.

N Engl J Med. 2005 Aug 11;353(6):566-75.

12.

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.

J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.

13.

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.

Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE.

Menopause. 2004 Jul-Aug;11(4):405-15.

PMID:
15243278
14.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR; AACE Osteoporosis Task Force..

Endocr Pract. 2003 Nov-Dec;9(6):544-64. No abstract available. Erratum in: Endocr Pract. multiple author names added. Endocr Pract. 2004 Jan-Feb;10(1):90.

PMID:
14715483
15.

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis.

Luckey MM, Gilchrist N, Bone HG, Davie MW, de Villiers TJ, Wu M, Daifotis AG, Santora AC, Orloff JJ.

Obstet Gynecol. 2003 Apr;101(4):711-21.

PMID:
12681875
16.

Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M.

J Clin Endocrinol Metab. 2002 Oct;87(10):4431-7.

PMID:
12364413

Supplemental Content

Loading ...
Support Center